Getting accurate and reliable reference materials is becoming increasingly important in pharmaceuticals today. Companies that provide innovative solutions in this area are driving significant progress in drug development and research. Evidentic GmbH leads in providing innovative therapeutic reference molecules that advance the pharmaceutical and biotech industries. Leading this pioneering company is Dr. Christian Schmitz, the Founder and Managing Director, whose deep expertise in molecular virology and business development has driven Evidentic to international success.
Let’s dive into the interview details below!
Can you tell us about your professional background and your current role in the company?
Based in Postdam, we are specialized in the preparation of analytical sample material, specifically therapeutic reference standards for the pharmaceutical industry. Evidentic is the only company to offer small quantities of licensed therapeutic reference standards for research and early drug development projects. With over 10 years of scientific expertise in molecular virology and business development, I have strategically driven the growth and international expansion of Evidentic. My team and I managed to expand our customer base to include research, biotech and pharmaceutical companies worldwide. My role is centered on actively shaping the company’s direction, leading critical strategic initiatives, fostering innovation and continuously enhancing our competitive edge in the global market.
What motivated you to pursue a career in the drug delivery and manufacturing industry?
My motivation to pursue a career in the pharmaceutical industry is deeply rooted in my early academic and research experiences in molecular virology and cancer research, where I witnessed firsthand the transformative power of pharmaceutical innovations on global health. As a specialty supplier of therapeutic molecules at the pre-clinical stages of drug development, I am driven not only by the ability to support the development of life-saving therapies but also by the desire to challenge and rethink established value chains. By leveraging my scientific expertise and strategic entrepreneurial mindset, I am passionate about creating innovative business models that push industry boundaries, developing new marketplaces that offer long-term advantages and enhance the support we provide to our clients in their drug development journeys. I believe that fast and easy access can streamline research and early drug development and reduce time-to-market for life-changing therapies.
Could you provide a brief overview of your company and its main focus areas in drug delivery and manufacturing?
Evidentic GmbH is a pioneering provider of therapeutic reference standards required for the early-stage drug discovery and development process. We specialize in providing licensed drugs in smaller, research-sized quantities, ensuring fast, cost-effective, and smooth access to licensed molecules. Founded in 2016, we have rapidly established ourselves as a trusted partner to pharmaceutical companies and contract research organizations worldwide. With a strong international presence, particularly in the USA, France, and the UK, we offer a comprehensive range of reference materials that meet the stringent quality standards required for accurate and reliable drug testing. Our expertise lies in the fast and reliable sourcing of high-quality therapeutic reference standards, enabling efficient and cost-effective drug development. By ensuring the integrity of research data, we contribute to the accelerated development of life-saving therapies. Our comprehensive catalog and dedicated customer support guarantee exceptional service and reliable delivery, making us the preferred partner for organizations seeking to optimize their research efforts.
What are the primary drug delivery technologies your company specializes in, and how have they evolved during your tenure?
Evidentic GmbH does not specialize in drug delivery technologies. Our core competency lies in the preparation and supply of high-quality therapeutic reference standards, which are essential tools for drug discovery and development, quality control, and analytical testing. While drug delivery technologies have advanced significantly over the years, our focus has remained consistent: providing precise and reliable reference materials to support the pharmaceutical industry’s evolving needs.
Can you highlight any recent innovations or new products that your company has developed under your leadership?
Under my leadership, Evidentic has pioneered several key innovations that have reshaped the supply chain for therapeutic molecules in the early stages of drug development. The customers of Evidentic get access to our precision quantity system that has eliminated wastage by providing exact amounts of reference materials, resulting in a cost reduction for therapeutic reference standards. We’ve also revolutionized the speed of supply by maintaining an available stock of therapeutic materials, giving researchers near-instant access to what they need.
What makes Evidentic a unique provider of therapeutic molecules is our long-term storage of different production batches of the same therapeutic. For some clients, the value of these samples is immense: they can directly test batch-to-batch variations of the same molecule produced in different batch runs. This unique repository gives us a competitive edge and helps researchers achieve results within weeks, rather than years.
Additionally, we’ve simplified the procurement process by developing streamlined procedures for repurposing original drugs, making them available for research without the need for permits, prescriptions, special licenses, or other bureaucratic hurdles. Evidentic’s competitive edge is built on three pillars: rapid availability, ease of access, and cost-effective solutions for small quantities of therapeutic molecules. These innovations, combined with our unwavering commitment to quality and customer satisfaction, have solidified Evidentic’s position as an industry leader.
What do you consider to be the biggest challenges facing the drug delivery and manufacturing sector in Europe, and how is your company addressing them?
One of the biggest challenges in the drug development industry, particularly for highly innovative, agile, and young companies, is the limited access to comparator molecules, or reference materials, of clinical-grade quality. The industry’s reliance on patents and secrecy to maintain competitive advantages creates a significant gap in the availability of these critical materials. Evidentic is addressing this critical issue to foster the early research ambitions of emerging and midsize companies by creating a trusted marketplace that offers reliable access to a wide range of high-quality therapeutic molecules. This is especially crucial for service providers such as analytical CROs, assay and characterization CROs, and CDMOs, which need these resources to assist their clients in pharma and biotech during the initial stages of research projects. By adhering to the highest standards and expanding our global reach, we ensure that these essential materials are not only accessible but also tailored to meet the specific demands of our customers. By continuously expanding our catalog and exploring new partnerships, Evidentic is committed to supporting the innovation pipeline and accelerating drug development.
Based on your experience, what advice would you give to professionals looking to make an impact in the drug delivery and manufacturing industry?
My advice to professionals entering this field is to develop a strong foundation in both the scientific and business aspects of the industry. A deep understanding of drug development processes, coupled with a keen awareness of market trends and regulatory landscapes, is essential. It’s also important to stay adaptable and continuously seek opportunities for innovation, as the industry is fast-paced and ever-evolving. Building strong relationships and a commitment to quality will also be key to making a lasting impact. By aligning personal goals with the industry’s mission of improving human health, professionals can make a truly meaningful impact.
Evidentic’s Formula for European Market Success
Evidentic GmbH maintains its competitive edge in the European pharmaceutical market through an unwavering focus on quality, innovation and customer satisfaction. With a profound understanding of the pharmaceutical industry and the ability to swiftly adapt to changing regulatory landscapes, we redefine industry standards by offering unique products and services. Our dedication to sustainability and ethical sourcing further enhances our competitive advantage. Strong relationships with our customers, collaborations with leading pharmaceutical companies, CROs, CDMOs, and research institutions, as well as a proactive approach to exploring new markets, solidify our position as a trusted and reliable supplier.
Read More: Click Here
